SS-31 (Elamipretide) is a synthetic tetrapeptide engineered to selectively concentrate in the inner mitochondrial membrane via electrostatic interaction with cardiolipin, the signature phospholipid of that compartment. Developed in the laboratory of Dr Hazel Szeto, SS-31 represents a distinct pharmacologic class — the "mitochondria-targeted peptide" — whose research activity arises from physical localisation at the mitochondrial inner membrane and stabilisation of cardiolipin-protein interactions critical to electron transport chain function. The compound is in Phase 3 clinical development by Stealth BioTherapeutics for Barth syndrome and primary mitochondrial myopathy.
SS-31 is an aromatic-cationic tetrapeptide whose distinctive feature is selective concentration at the inner mitochondrial membrane — achieved through electrostatic interaction with the negatively-charged cardiolipin phospholipid that comprises ~20% of inner-membrane lipid content. The compound concentrates ~1000-fold in the inner membrane relative to extracellular concentration, a level of organelle selectivity rarely achieved with small-molecule pharmacology.
Mechanistically, SS-31 stabilises the cardiolipin-cytochrome c interaction that organises electron transport chain Complex IV and the broader respiratory supercomplexes. In aged or stressed mitochondria where cardiolipin acyl-chain composition has been altered, SS-31 binding preserves supercomplex architecture and reduces electron leak (a major source of mitochondrial reactive oxygen species).
The downstream effects observed across preclinical models include preserved ATP synthesis under stress, reduced ROS generation, attenuation of mitochondrial permeability transition pore opening (which triggers apoptosis), and recovery of mitochondrial membrane potential in injury models. The compound has been studied in cardiac ischaemia-reperfusion, heart failure, mitochondrial myopathy and age-related sarcopenia research lines.
Barth syndrome is a rare X-linked disorder caused by mutations in the TAZ gene encoding tafazzin, the cardiolipin-remodelling enzyme. The disease produces cardiomyopathy, skeletal myopathy and neutropenia from disrupted cardiolipin maturation. SS-31 is in active Phase 3 development for Barth syndrome (TAZPOWER programme) with FDA-granted Fast Track and Rare Pediatric Disease designations.
The Phase 2 TAZPOWER readout documented improvements in 6-minute walk distance and patient-reported fatigue measures — outcomes consistent with the cardiolipin-stabilising mechanism in a disease defined by cardiolipin dysfunction.
Beyond Barth syndrome, SS-31 has been the subject of an extensive cardiovascular research programme. Preclinical work in cardiac ischaemia-reperfusion injury, doxorubicin cardiotoxicity, diabetic cardiomyopathy and heart failure consistently documents preservation of cardiac function and mitochondrial bioenergetics.
In ageing research, SS-31 has been studied in skeletal muscle of aged mice (work by Rabinovitch and Marcinek), where 8 weeks of dosing reversed age-related fatigue resistance loss and partially restored youthful mitochondrial function — among the few interventions to demonstrate phenotypic age-reversal in functional outcomes.